Skinvisible (SKVI) EBT Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) EBT Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.06 Bn | 626.30 Bn | 17.26 Bn | -265.00 |
| 2 | AbbVie | 440.06 Bn | 433.49 Bn | 12.70 Bn | 636.00 |
| 3 | Merck | 364.19 Bn | 357.05 Bn | 12.21 Bn | 3,137.00 |
| 4 | Novartis Ag | 268.45 Bn | 260.76 Bn | 11.24 Bn | 625.00 |
| 5 | Pfizer | 158.40 Bn | 146.70 Bn | 10.94 Bn | -2,179.00 |
| 6 | Sanofi | 52.57 Bn | 45.19 Bn | 10.79 Bn | -977.00 |
| 7 | Revolution Medicines | 44.32 Bn | 44.32 Bn | - | - |
| 8 | Incyte | 24.98 Bn | 20.44 Bn | 1.57 Bn | 1,581.00 |
| 9 | United Therapeutics | 21.15 Bn | 18.49 Bn | 683.80 Mn | -861.00 |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | 49,624.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 49,624.00 |
| Mar 31, 2026 | 2.50 Mn |
| Dec 31, 2025 | 301,072.00 |
| Sep 30, 2025 | -51,429.00 |
| Jun 30, 2025 | -547,916.00 |
| Mar 31, 2025 | -500,471.00 |
| Dec 31, 2024 | -716,554.00 |
| Sep 30, 2024 | -567,201.00 |
| Jun 30, 2024 | -609,253.00 |
| Mar 31, 2024 | -219,359.00 |
| Dec 31, 2023 | -513,602.00 |
| Sep 30, 2023 | 981,208.00 |
| Jun 30, 2023 | -532,503.00 |
| Mar 31, 2023 | -2.76 Mn |
| Dec 31, 2022 | -421,681.00 |
| Sep 30, 2022 | -57,796.00 |
| Jun 30, 2022 | 448,452.00 |
| Mar 31, 2022 | 354,499.00 |
| Dec 31, 2021 | 271,476.00 |
| Sep 30, 2021 | 470,839.00 |